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Native cellular fluorescence (NCF) represents the innate capacity of tissues to absorb and emit
light of specified wavelengths. Recent advances in optical engineering and computer technology
have provided the opportunity to measure NCF characteristics of various tissues in vivo. This
report will briefly review the current status of NCF analysis of various neoplastic tissues. The
status of investigations involving the upper aerodigestive tract will be discussed. Though initial
results demonstrate that neoplastic tissues can be discriminated from normal mucosa by NCF
analysis, the biologic basis of this difference remains uncertain. This report will also emphasize
that the ability to screen for cancer in aerodigestive mucosa may be enhanced through the
assessment of multiple emission and excitation wavelengths. The true nature of the cellular
fluorophores responsible for these mucosal spectral characteristics should be more fully defined
in coming years. Environ Health Perspect 105(Suppl 4):941-944 (1997)
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The capacity to effectively screen for
premalignant and early invasive cancers of
the upper aerodigestive tract and lung
should lead to improved survival.
Numerous strategies developed over the
past 2 decades to achieve this goal include
novel immune and molecular cytological
techniques, the development ofcirculating
tumor markers, and advances in diagnostic
radiology (1-7). It is evident from the
review of these various approaches that
optimal methods must still be established.
The need for improved sensitivity and
specificity in cancer diagnosis has led to
interest in native cellular fluorescence
(NCF), i.e., the innate capacities oftissues
to absorb and transmit light, as a means of
distinguishing normal from neoplastic tis-
sue. It has been well recognized for many
years that numerous subcellular compo-
nents, termed fluorophores, were capable
of emitting light ofspecified wavelengths.
Such fluorophores include various pro-
teins, coenzymes, micronutrients, and
even DNA (8). The concept that qualita-
tive and quantitative differences in cellular
fluorophores would distinguish diseased
from normal tissue in vivo had been
explored since the 1950s. Schaffer and
Sacks, for instance, noted that assessment
of oral cavity mucosa by means of a
Wood-Light ultraviolet lamp would dis-
tinguish individuals with riboflavin defi-
ciency (9). By providing nutritional
supplements, those authors noted a rever-
sal of the abnormal mucosal fluorescence
and thus demonstrated the clinical utility
of this approach. The spectral characteris-
tics of riboflavin have been previously
described (8,10).
In the mid-1980s investigators began to
apply the principle of NCF to the assess-
ment of neoplastic tissue. Alfano et al.
(11,12) and Glassman et al. (13) analyzed
breast and lung tissues for NCF patterns in
vitro. Glassman et al. (13) utilized a xenon
lamp to generate a 300-nm excitation
beam and then quantitated 340:440-nm
emission ratios. They noted that neoplastic
tissue contributed significantly elevated
340:440 nm ratios compared to nonmalig-
nant tissues. Similar observations regarding
the 340:440-nm ratio were noted for cervi-
cal cancers (13). Numerous investigations
over the past several years have explored
the use ofNCF technology for screening of
diseases of the colon, cervix, and lung
(Table 1) (14-19). Various laser sources
were utilized, including helium-cadm.um
and nitrogen-pulsed lasers. The analysis of
fluorescence emission has pointed to
abnormalities at various wavelengths,
including 380-, 450-, 520-, and 680-nm
emission. Overall sensitivity and specificity
ofNCF have ranged from 85 to 95% and
80 to 85%, respectively. Indeed, several
authors claim that NCF analysis was supe-
rior to more standard approaches, includ-
ing physical examination and routine
light-based endoscopy (17,18).
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Table 1. Demographic characteristics of cases and controls.
Native cellular fluorescence characteristics
Organ system, reference Excitation source Wavelength analysis Sensitivity, %/specificity, %
Colon
Kapadia et al. (15) HC Multiwavelength 100/99
Cothren et al. (14) PN 680 versus 460 nm 100/94
Schomacker et al. (16) PN 12 wavelengths 80/92
Lung
Lam et al. (17) HC 630:520-nm ratio 73/94
Cervix
Ramanujam et al. (18) PN 450-nm emission 87/75
Esophagus
Vo Dinh et al. (19) PN 480-nm emission
640-nm emission NS
Head and neck
Franchesci et al. (21) X 450-nm emission NS
Kolli etal. (22) X Multiwavelength NS
Abbreviations: HC, helium cadmium; PN, pulsed nitrogen; NS, not stated; X, xenon.
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In VivoAnalysis of Upper
Aerodigestive Mucosa
Initial investigations on upper aerodigestive
cavity mucosa, in both humans and animal
model systems, have recently been reported
(20-24). The oral cavity lends itself to
such studies for several reasons (20). One
is that the relationship between envi-
ronmental exposures and diseases of the
oral cavity has been well documented.
Approximately 90% of individuals with
cancer at this site will give a past or current
history oftobacco exposure. The oral cav-
ity is readily examined during a routine
office or dental visit, thus requiring no spe-
cial preparation or patient discomfort.
Multiple examinations on a large popula-
tion can then be performed to derive the
significance ofa particular screening strat-
egy. In addition, a well-defined premalig-
nant state, termed leukoplakia, can be
identified within the oral cavity. This con-
dition has facilitated our understanding of
neoplastic progression not only within the
oral cavity but in other epithelial tissues as
well. Finally, it is well known that patients
with one oral cavity cancer are at risk of a
second cancer. This has given rise to the
concept offield cancerization, i.e., the the-
ory that all tissues exposed to a particular
carcinogen will be at risk for malignant
transformation and that such tissues will
progress in various stages toward invasive
disease (25,26). The question remains as
to the most appropriate way to screen for
multifocal diseases within such individuals.
To our knowledge, only a few studies
have addressed the NCF characteristics of
oral cavity neoplasias in vivo. Franchesci et
al. assessed 13 tongue cancers and con-
tralateral normal mucosa by means of a
xenon-lamp excitation source (21). An
excitation scan at 450-nm emission was
utilized. This scan varies the excitation
wavelength over a range of280 to 430 nm.
Optimal excitation wavelengths capable of
generating 450 nm emission can then be
established. Using Fourier transform
analysis, the authors noted a significant
difference between tongue lesions and con-
tralateral normal mucosa (21). A recent
study by Kolli et al. (22) has extended this
observation and showed that fluorescence
characteristics of oral cavity cancers also
involved the abnormal absorption and
emission of other wavelengths, including
340-, 380-, and 440-nm wavelengths. The
choice of these wavelengths was based in
part on previous in vitro and in vivo
studies, which demonstrated that each was
capable ofdistinguishing neoplastic from
nonneoplastic tissues. Furthermore, each
wavelength can be ascribed to particular
fluorophores, which may differ in both
quantitative and qualitative terms in tissues
in varying stages ofprogression from nor-
mal to invasive disease (Table 2) (8).
The preponderance ofstudies, therefore,
have demonstrated that neoplastic tissues
can be discriminated from normal epithe-
lial tissues within an individual patient.
The optimal wavelengths for either excit-
ing tissue or measuring emission, however,
have yet to be defined. Likewise, consider-
able variance in the means of analyzing
spectral profiles exists among studies
(13-18,22). Methods include the utiliza-
tion ofabsolute intensity, various transfor-
mations of data, multivariate logistic
regression models, and other normalization
procedures to best predict the presence of
disease. No doubt, part of the confusion
stems from the complexity ofboth the car-
cinogenisis process and fluorescence deter-
minants. It is clear, for instance, that wide
variance in NCF characteristics exists in
the normal mucosa ofvarious individuals
(18,21,22). The biologic basis for these
differences is unclear. However, differences
within an individual will be more informa-
tive than differences between individuals.
Attempts to define a particular algorithm
for predicting a diseased state, though
informative, will have limited clinical value
ifanalysis is confined to the use ofa single
excitation wavelength.
Current results support the use of
multiple excitation and emission profiles in
defining a particular tissue. Composite
results may more accurately represent the
state of health of a given tissue than will
the analysis of a single wavelength. The
clear application ofthis principle to cancer
screening in vivo needs to be defined. Our
efforts have been to explore the biologic
basis for NCF within aerodigestive mucosa
through the use of various laboratory
model systems.
Animal Studies on Upper
Aerodigestive Mucosa
Several animal models have been utilized to
assess the ability ofNCF to distinguish car-
cinogen-induced alterations within exposed
tissue (23,24). Glasgold et al. utilized a
Sprague-Dawley rat model to assess alter-
ations (24). In this well-defined cancer
model, Sprague-Dawley rats are injected ip
with a 5% solution of N-nitrosomethyl
benzylamine (NMBA). Following 15
weeks of injections, the majority of rats
will develop gross evidence ofesophageal
Table 2. Spectral characteristics of majorfluorophores.
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disease consisting of either adenomas or
invasive cancers. In the initial studies by
Glasgold et al. (24), NCF characteristics
ofthe rat esophageal mucosa were demon-
strated at varying times after initial
exposures. Two spectral profiles were dis-
cussed-the 380- and 450-nm excitation
scans. Spectral alterations become consis-
tently apparent after 5 weeks of NMBA
exposure. Indeed, in several instances fluo-
rescence alterations were noted as early as
2 weeks (24).
The above study provided evidence
regarding the determinants of spectral
alterations as well. Though changes in both
the 380- and 450-nm excitation profiles
occurred at approximately the same time,
each reflected a different component ofthe
esophageal wall. In the 380-nm scan, con-
tinued carcinogen exposure led to progres-
sive increases in the 290:330-nm ratio
(Figure 1). This decrease was directly pro-
portional to the increasing thickness ofthe
esophageal mucosa, which occurred during
malignant transformation. We suggested
that the loss ofthe 330-nm excitation peak
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Figure 1. Representative excitation scan of an NMBA-
induced esophageal carcinogenesis model within
Sprague-Dawley rats. Rats were exposed to saline
(control) or NMBA for 7 and 90 days, respectively.
Fluorescence analysis reveals progressive loss of
intensity of the 330-nm peak relative to the 290-nm
peak with continued exposure. Reprinted from
Glasgold et al. (24), with permission.
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was secondary to decreased excitation of
collagen within stroma. As the mucosa
thickens, less ofthe excitation beam pene-
trates the stromal-mucosal interface. In
support of this conclusion, layers of the
esophageal wall were separated by
treatment with versene. The 330-nm exci-
tation peak emitted solely from the pure
stromal preparation. No peak could be
generated by exciting only mucosal cells.
Data supported previous observations by
Schomacker et al., who examined human
colon tissue (15). These researchers
demonstrated that in vitro layering of
mucosal tissue on a stromal bed decreased
collagen signaling.
In contrast to the 380-nm excitation
scan, alterations in the 450-nm excitation
induced by carcinogen exposure emanated
entirely from esophageal mucosa (24).
These changes became evident as early as
2 weeks after NMBA exposure and long
before gross pathologic changes were noted.
These data demonstrate that multiwave-
length assessment of esophageal mucosa,
i.e., the use of multiple excitation wave-
lengths and the measurement ofmultiple
emission characteristics, will define differ-
ent histoarchitectural elements within dis-
eased mucosa. The study also demonstrates
that NCF alterations occur very early in
malignant transformation and long before
gross malignancy or even premalignant
changes can be identified. These results
support the use ofNCF characteristics as a
means ofscreening for preclinical disease.
They also provide a basis for monitoring
the impact ofprevention strategies designed
to halt or reverse the neoplastic process.
In VitroStudies of Upper
Aerodigestive Mucosa
The biologic basis for NCF characteristics
of upper aerodigestive mucosa has been
explored through in vitro analysis (27-29).
The premise ofthese studies is that precan-
cerous alterations within aerodigestive
mucosa that precede clinically apparent
disease will be characterized by abnormal
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Figure 2. Representative normalized excitation scan
(excitation 240-430 nm, 450 nm) of control (solid line)
and treated (dotted line) A431 carcinoma cells. A431
cells were treated in the presence (solid line) or absence
(dotted line) of 100 ng/ml of epidermal growth factor
(EGF). EGF induced inhibition ofgrowth atthis concentra-
tion. Reprinted fromZhang etal. (28), with permission.
approach has been to characterize fluores-
cence abnormalities that reflect that process.
Using three cell systems consisting of3T3
fibroblasts, A431 squamous carcinoma
cells, and short-term cultures of normal
oral epithelium, proliferation rates were
altered by various growth conditions (28).
Proliferation rates were measured by cell
count, tritiated thymidine incorporation,
and cell-cycle analysis by flow cytometry. A
characteristic spectral profile was identified
in each instance, independent of the cell
line utilized, and involved emission at 450
nm. Figure 2 shows a characteristic profile
of the 450 nm excitation scan. In this
example, A431 cells were growth inhibited
by medium supplementation with epider-
mal growth factor. Scans revealed a
hypochromic shift of the primary maxi-
mum in cells that were more rapidly pro-
liferating. Furthermore, the primary
excitation peak maximum:370-nm ratio
was consistently greater in the more rapidly
proliferating cells. Although one may
assume that the fluorophore that con-
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Figure 3. Representative normalized excitation scans
(excitation 270-500 nm, emission 520 nm) of normal
oral epithelia (NOE). Short-term cultures of NOE were
grown in media supplemented with (dotted line) or
without (solid line) 0.8-M NaCI. The high-salt contain-
ing media induced cellular differentiation. Reprinted
from Sacks etal. (30), with permission.
further characterization ofthe biochemical
basis ofthis fluorescence profile is in order.
Next, short-term cultures ofnormal oral
epithelia were established to modulate
cellular differentiation (26). Differentiation
in these experiments was induced by cul-
turing oral epithelium in high salt concen-
trations, and was noted through the
acquisition ofcornified envelopes and high
molecular weight keratin, cytokeratin 13.
Distinct from the proliferation model
described above, alterations in the 520-nm
excitation scan could be identified (Figure
3). Compared to less-differentiated cells,
cells grown in high salt solution demon-
strated an increased secondary absorption
maximum at 380 nm. Thus, two systems
that measure cellular proliferation and dif-
ferentiation, respectively, provide unique
changes in fluorescence emission patterns,
again pointing to the value of multi-
wavelength analysis. These results also sup-
port the use ofNCF characterization as a
means ofscreening for subclinical pheno-
typic alterations in tissues at high risk for
cancer development.
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